Corp. Reg. No. 556966-4955
November 27, 2026

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2026

Third quarter (July-September 2026)

- Operating profit/loss amounted to SEK -11,638,399 (146,689).
- Loss for the period amounted to SEK -11,397,982 (304,153).
- Cash flow from operating activities totaled SEK -7,235,062 (-4,738,100).
- Earnings per share before and after dilution totaled SEK -0.17 (+0.01).

Period (January-September 2026)

- Operating profit/loss amounted to SEK -23,060,649 (-10,815,056).
- Loss for the period amounted to SEK -22,719,805 (-10,441,379).
- Cash flow from operating activities totaled SEK -18,167,988 (-11,474,233).
- Earnings per share before and after dilution totaled SEK -0.40 (-0.23).

Key events during the quarter

- Last patient treated in the Phase I part of the CARMA study – tumor responses in 10 of 11 patients evaluated to date
- Elicera gathers management in Uppsala – CEO transition begins and recruitment of a new CEO has started
- Elicera Therapeutics appoints Johan Liwing as new CEO
- Elicera receives its first notice of patent allowance for ELC-201 – a Japanese patent protecting the oncolytic virus candidate against solid tumors
- Elicera receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate
- Elicera receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma
- Elicera Receives Medical Products Agency Approval to Advance CARMA Study into Phase IIa in B-cell Lymphoma

Key events during the period

- Elicera announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors
- Elicera provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway
- Elicera reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

- Elicera's CSO Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)
- Elicera receives Notice of Allowance for Japanese patent protecting the ELC-401 CAR T-cell candidate
- An extra shareholders meeting May 8 approved the boards proposal for a new rights issue at SEK 72.8 m
- Elicera's CSO takes leave to undergo medical treatment – Di Yu appointed Acting Chief Scientific Officer (CSO)
- Elicera Therapeutics announces that the final reporting and final payment (SEK 1.4 m) from the EIC Accelerator for the CARMA study have been approved
- Elicera's new issue subscribed at 75 % and Elicera receive SEK 54.6 m before issuing costs
- Elicera receives positive feedback from Swedish MPA on Planned Clinical Study with ELC-401 in glioblastoma
- Elicera's annual general meeting June 25 elects Margareth Jorvid as new chair

Key events after the end of the period

- Elicera completes Phase I part of CARMA study of ELC-301 and reports complete metabolic response in 8 of 12 patients
- Elicera receives notice of allowance for ELC-401 patent in China
- No other key events that impact earnings or the financial position occurred after the end of the period.

CEO Comments

Phase I of the CARMA study completed: Deep responses in eight of twelve patients

During my first quarter as CEO, Elicera Therapeutics presented its most significant clinical trial results to date. I would like to thank my predecessor, Jamal El-Mosleh, for the solid foundation he has laid, and I look forward to leading the company toward important new milestones.

In October, we completed Phase I of the CARMA study evaluating ELC-301, our iTANK-armed CAR T-cell therapy. All twelve patients have now been assessed. The results show that eight of twelve patients (67 percent) achieved a complete metabolic response as their best response to treatment, and eleven of twelve achieved an objective tumor response. Six patients remained in complete metabolic response at the latest follow-up, including two who was followed up for at least one year. The patients enrolled in the study had exhausted all other potentially curative treatment options for their cancer following prior treatments, including three patients who relapsed after previous CAR T-cell therapy. The treatment achieved a deep response, meaning the disease was suppressed to a very low level. This was also

achieved without dose-limiting toxicity, which makes the results even more significant.

Following a recommendation from the independent safety committee, the Swedish Medical Products Agency approved the CARMA study's progression to Phase IIa in September, using the highest dose evaluated in Phase I. In Phase IIa, six additional patients will thus be treated, and enrollment is expected to begin before the end of the year.

This fall, we are participating in partnering and investor meetings in Sweden, other European countries, and the United States, including Redeye Life Science Day, BIO-Europe and Meeting on the Mesa. Business development is a key priority. Building on the Phase I results, we now aim to generate interest in ELC-301 among potential partners and demonstrate how iTANK can also arm other companies' CAR T cells and other cell types, so that industry relationships are well established by the time Phase IIa data become available. In parallel, we are strengthening our dialogue with the capital markets.

Preparations for the first clinical trial of ELC-401, our CAR T-cell therapy candidate for glioblastoma, are ongoing. We are currently working intensively on process development, technology transfer to our manufacturing partner, and finalizing the study design.

In August, we received notification from the U.S. Patent and Trademark Office that a patent will be granted for the antibodies targeting the tumor antigen on which ELC-401 is based. The exclusive right to develop and commercialize these treatments in the United States strengthens the technology's commercial potential in solid tumors. Shortly thereafter, we received our first patent approval for ELC- 201. The approval in Japan is a yet another testament to the innovation in our portfolio and to Elicera's position at the forefront of the global development of new immuno-oncology treatments.

We enter the final months of the year with strong clinical data, an approved Phase IIa study, and broader patent protection. Our focus is now on treating patients in Phase IIa, completing the Phase I analysis, and building relationships that can translate data into partnerships. This is how we create value for patients and shareholders.

Johan Liwing
CEO

The interim report has been approved by the board and the CEO for publication. The information was submitted for publication distributed through the contact person below at 08;03 CET on November 27, 2026.

Elicera Therapeutics AB's Interim report for January to September 2026 is available at the company home page : https://www.elicera.com/investors-2/financial-reports.

For further information please contact:
Johan Liwing, CEO, Elicera Therapeutics AB
Phone: +46 (0) 706 70 36 75
johan.liwing@elicera.com

Certified Advisor
DNB Carnegie Investment Bank AB (publ)

About the iTANK-platform
The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers" (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology

About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.